Patient-Centered Neurotechnology
A Curated Reference for Innovators Looking to Commercialize Medical Devices
Neurotechnology products do not succeed on technical performance alone. Their viability depends on whether they are designed, evaluated, and implemented in ways that reflect the needs, tolerances, workflows, and lived realities of the people expected to use them.
In regulated device development, patient-centered design is a matter of safety, usability, risk management, and evidentiary credibility, well beyond design quality alone.
This reference maps the patient-centered organizations, standards, frameworks, and governance considerations most relevant to neurotechnology innovators. Scope covers neurotechnology devices and related clinical development, not pharmaceutical or biological product development.
Every resource on this page is useful, but not at once. Patient engagement compounds when it starts early and carries a documentation trail into your submission. Select your current stage to see what to prioritize, why it matters at that point, and which sections here earn your attention first.
Early engagement is the highest-leverage, lowest-cost point on the whole curve. A design input traced to patient need at this stage carries evidentiary weight through every later phase. The same input added at submission reads as retrofitting.
EFS (Early Feasibility Study) is a limited clinical study early in development, often used when a device design is not yet final. IDE (Investigational Device Exemption) is the FDA authorization that lets an unapproved significant-risk device be used in a clinical study to collect safety and effectiveness data.
Enrollment is the binding constraint on how fast most neurotechnology advances. Advocacy partnerships built in earlier stages pay off here as recruitment reach and retention, the two variables that most often decide whether a pivotal trial finishes on time.
PMA (Premarket Approval) is the FDA's most stringent device pathway, required for most Class III (highest-risk) devices, including many implanted neurotechnologies. It demands valid scientific evidence, usually from a pivotal clinical trial, that the device is safe and effective. 510(k) clears a device by showing substantial equivalence to a legally marketed predicate. De Novo creates a pathway for novel low-to-moderate-risk devices that have no predicate.
The organizations that helped you recruit are also your most reliable early-warning system for real-world problems. A relationship maintained past launch converts into both safety signal and a head start on the next device.
Patient advocacy organizations aggregate lived experience at a scale and depth no single development team can replicate. The value is in reaching them, so each entry below carries an engagement route and a tag for how it works with developers. Jump straight to the category you need.
Groups centered on neurotechnology devices and therapies, including BCI-specific communities.
Serving epilepsy, Parkinson's, spinal cord injury, depression, and hearing loss communities.
Broad neurological and brain health organizations relevant across multiple device categories.
Global and regional patient advocacy organizations shaping neurotech policy worldwide.
A nonprofit improving education, awareness, and access to neurotechnology devices and therapies for people with neurological conditions. Its community engagement services exist specifically to bridge advocates and developers, alongside published lived-experience engagement listings and its Real Stories narratives.
How to engageContact them through their community engagement services to request lived-experience input or engagement listings for your program.
Individuals with spinal cord injuries who have carried brain-computer interface implants through research studies. The BCI Pioneers Coalition gives input to clinicians, patients, and companies on the ethics, usability, and lived experience of BCIs through stakeholder partnerships and speaking engagements.
How to engageReach out to establish a stakeholder partnership or invite members to advise on BCI usability and study design.
Serving the patient populations most frequently targeted by neurotechnology clinical development: epilepsy, Parkinson's disease, spinal cord injury, treatment-resistant depression, and hearing loss.
Hosts the only global forum on Parkinson's disease, bringing clinicians, researchers, and patients together to explore scientific advances, clinical approaches, and care strategies.
How to engageParticipate in the World Parkinson Congress to meet the community and present work.
The North American Spinal Cord Injury Consortium, Unite 2 Fight Paralysis, and the Christopher & Dana Reeve Foundation collectively advance research, advocacy, and cross-sector collaboration for the spinal cord injury community.
How to engageConnect through the consortium or Reeve Foundation to reach study participants and community advocates.
The Epilepsy Foundation runs the dtRRE roundtable and EmpowER&D platform for research engagement, while CURE Epilepsy funds science for drug-resistant epilepsy and publishes webinars on lived experience in research.
How to engageApproach the Epilepsy Foundation's research engagement team about the dtRRE roundtable or EmpowER&D.
DBSA, NAMI, HLAA, and the American Tinnitus Association serve populations targeted by neuromodulation and cochlear implant development, offering trial promotion, education, and lived-experience media.
How to engageUse their trial promotion and research channels to reach patients; expect a patient-first orientation.
Through its Lived Experience Initiative, One Mind runs a Lived Experience Council and a Community Advisory Network that embed people with lived experience into mental health research and product development. Council members actively advise startups including Amae Health, Pangea Bio, and Holobiome, helping teams refine research and build lived-experience partnerships into their work.
How to engageApproach the Lived Experience Initiative about council advising for your research or product roadmap.
A philanthropy focused on brain research and public engagement. The Dana Foundation produces accessible resources on brain health and neuroscience-and-society questions that are useful for public-facing patient engagement materials.
How to engageDraw on their published resources for public engagement content and neuroethics grounding.
A network of neuroscientists, founders, investors, philanthropists, universities, and patients that guides and invests in neurotech ventures. BrainMind convenes gatherings centered on ethical leadership and investment, and produced the Asilomar Lived Experience Rubric referenced in the engagement section below.
How to engageApply to their ecosystem, and engage through their network and gatherings for potential collaborative opportunities and investments.
Built around a patient-centered development model that explicitly integrates individuals with lived experience into neurotech design and translation. The NeuroTech Institute elevates patient voices alongside engineers and clinicians.
How to engageContact them to bring lived-experience co-design into your development process.
An umbrella nonprofit uniting more than one hundred of the leading professional neurological, psychological, and psychiatric associations with patient organizations, researchers, and industry. The American Brain Coalition advocates on brain-disorder policy from Washington and leads a patient-driven effort toward a Neuroscience Center of Excellence at the FDA.
Its CARE Network is the route built for this purpose, scoped from a needs assessment with neurotechnology companies. The member-driven hub offers a community engagement management resource, custom AI tools, and a peer-to-peer learning network. ABC also runs patient engagement work with the FDA that carries lived experience into regulatory feedback, and a Corporate Advisory Council giving device and biotech companies structured access to advocacy organizations and clinical, scientific, and policy leaders.
How to engageJoin the CARE Network through the platform page, or become a corporate member to reach the wider network. Address questions to ABC's Advocacy and Community Engagement Coordinator.
The cross-condition organizations are where field-level engagement norms are set. BrainMind's rubric, One Mind's council model, and the American Brain Coalition's policy work shape what good patient partnership looks like across neurotechnology, which is why they reward engagement earlier than a single-condition group would.
How to use thisTreat these as norm-setters and start relationships before you need recruitment.
Connects lived-experience advocates with clinicians, researchers, and policymakers globally. OneNeurology unites international neurological patient organizations and publishes work on lived-experience-informed policy.
How to engageEngage for international policy alignment and cross-border advocacy reach.
The European Federation of Neurological Associations provides structured patient representation in EU neuroscience, regulatory, and brain health policy through a Community Advisory Board, with a report on patient involvement in health technology assessment.
How to engageWork through their Community Advisory Board for EU patient representation.
An EU-level collection of patient advocacy organizations engaged in digital health, medical device regulation, and research policy. The European Patients' Forum bridges patients and policymakers through multi-stakeholder projects.
How to engageJoin multi-stakeholder projects to align device work with EU patient priorities.
A non-profit alliance of international rare disease patient organizations, including neurological disorders. EURORDIS runs the Roundtable of Companies and the Rare Barometer Programme of lived experiences.
How to engageUse the Roundtable of Companies to reach rare neurological populations.
A pan-European organization advocating for patient-led education, awareness, and research on mental health disorders. GAMIAN-Europe promotes lived experience across EU and non-EU research projects.
How to engagePartner on research projects needing mental health lived-experience input.
A UK coalition of health and social charities focused on patient-centered care. National Voices provides workshops and coaching for providers and developers through its Lived Experience Partners.
How to engageBook workshops or coaching via Lived Experience Partners.
A UK mental health research charity specializing in lived-experience involvement in psychiatric research. McPin is building a Lived Experience Collaboration Platform alongside involvement toolkits and advisory models.
How to engageDraw on their toolkits and advisory models to structure involvement.
A Dutch national initiative bringing patients, researchers, clinicians, and companies together to co-develop neurotechnology. NeuroTech-NL runs living field labs, networking events, public forums, and translational research.
How to engageJoin a living lab or forum to co-develop with patients and clinicians.
The International League Against Epilepsy drives epilepsy diagnostic standards and neuromodulation research frameworks worldwide, featuring people with lived epilepsy experience in International Epilepsy Congress symposia.
How to engageEngage through Congress symposia and standards work in epilepsy.
Human factors and usability engineering are core components of medical device development. In neurotechnology they are especially consequential, since devices may interact with vulnerable populations, involve chronic implantation, require caregiver participation, or depend on reliable use under demanding conditions. Compliance with applicable standards is expected in regulatory submissions and evaluated by FDA reviewers and notified bodies.
FDA's 2016 guidance on applying usability engineering in device submissions explains documentation requirements and how to structure summative validation testing. It applies directly to 510(k), De Novo, and PMA submissions.
FDA's guidance on the content of human factors information in marketing submissions sets a risk-based approach to what HF documentation belongs in a 510(k), De Novo, or PMA.
IEC 62366-1:2015 with AMD1:2020 is the principal international standard for usability engineering in device design, requiring identification of intended users, use environments, and use-related risks, plus formative and summative testing and submission documentation.
ISO 14971:2019 is the foundational risk management standard. It requires manufacturers to include patient harm in the risk calculus and weigh residual risks from the patient perspective, which is decisive for irreversible neurotech harms.
Ergonomics of human-system interaction. ISO 9241-11 defines usability, and ISO 9241-210 defines the human-centered design process, the conceptual foundation IEC 62366-1 builds upon.
A detailed reference standard giving comprehensive guidance on applying human factors methods across the device lifecycle, available through AAMI. Useful for teams building internal processes consistent with FDA expectations.
Patient Preference Information brings patient-defined benefit-risk thresholds into device submissions, the structured mechanism for documenting benefit-risk where patients trade function, risk, and quality of life.
Meaningful patient engagement requires more than informal feedback or occasional consultation. Structured frameworks help development teams distinguish true incorporation of patient perspective from symbolic inclusion, and provide documentation infrastructure that supports regulatory and investor scrutiny.
The Patient Engagement Advisory Committee gives FDA input from patient and caregiver perspectives on device review, while the Patient Science and Engagement Program carries those perspectives across the development lifecycle.
The PCORI Engagement Rubric gives a structured framework for planning and evaluating patient and stakeholder engagement, with concrete criteria and a common language for describing engagement quality.
A BrainMind field-specific framework guiding lived-experience engagement in neurotechnology and brain health research, calibrated to neurotech dynamics including neural data sensitivity and patient population complexity.
The MDIC center lets neurotech experts and patients collaborate across the device lifecycle, offering the Patient Engagement Estimation Tool, an early-engagement roadmap, and clinical trial design best practices.
NIHR publishes guidance, training materials, and case studies on structuring meaningful patient involvement, relevant for multinational research or UK regulatory engagement.
Wellcome Trust offers a guide to embedding lived-experience expertise in mental health research, with considerations for engagement across contexts, relevant for investigators submitting to the Trust.
The NeuroTech Course is a free online series on translating and commercializing neurotech, including a section on the user perspective, with bi-annual workshops and a practical handbook.
The National Health Council maintains the Patient Experience Mapping Toolbox, the Glossary of Patient Engagement Terms, and the Patient Engagement in Quality Measurement Rubric.
Neural recordings can reveal cognitive states, mental health status, emotional patterns, and in some contexts, predictive information about future behavior. This area continues changing, so each item below is dated and linked to a primary source. Treat neural data governance as an active design decision, not a late compliance check.
HIPAA sets national rules for protected health information, but only when data is held by covered entities such as providers and health plans. Most consumer neurotech falls outside its scope, the gap state laws are now addressing.
21 CFR Part 50 governs informed consent for human subjects in device research, setting the legal floor for what participants must be told before enrolling in a device trial.
Senators introduced the MIND Act (S. 2925) in September 2025 to direct an FTC study of national neural data standards. It has not become law, so no comprehensive federal neural data statute exists yet.
The first US state to protect neural data, HB 24-1058 amends the Colorado Privacy Act to treat neural data as sensitive "biological data." It is the narrowest of the four, applying only when the data is used for identification.
SB 1223 amends the CCPA so that sensitive personal information includes neural data, defined as information from measuring central or peripheral nervous system activity and not inferred from nonneural signals. It is the broadest of the four.
SB 163 amends Montana's Genetic Information Privacy Act to create a "neurotechnology data" category and is the first US law to address mental augmentation. It also restricts storing neural data in US-sanctioned countries.
SB 1295 amends the Connecticut Data Privacy Act to classify neural data as sensitive, making Connecticut the fourth state to enforce specific protections. The four laws differ enough that multistate compliance is now a gating item.
Adopted by UNESCO member states in November 2025, this is the first global standard framing neural data protection as a human rights issue, now informing national legislation.
Under the EU Medical Device Regulation, post-market clinical follow-up requires ongoing monitoring of patient experience with CE-marked devices, a continuous obligation to treat patient-reported information as a live data stream.
The NeuroRights Foundation proposes five neurorights: mental privacy, personal identity, free will, equal access, and protection from algorithmic bias. It has driven much of the recent US state legislation.
Trials are how a device demonstrates safety and effectiveness, earns clearance or approval, and becomes reimbursable. For sponsors, enrollment and retention are often bottlenecks of the timeline, so recruitment strategy deserves the same rigor as study design.
Regulators require clinical evidence before clearance, and payers including Medicare, Medicaid, and private insurers require evidence of benefit before covering a device. Both depend on completed enrollment, which makes recruitment reach the variable that most often sets how fast a program moves.
In the United States, oversight includes FDA review with Investigational Device Exemption requirements for significant-risk devices, Institutional Review Board approval, and informed consent under 21 CFR Part 50. Internationally, the EU Clinical Trials Regulation and ICH Good Clinical Practice apply.
Listing on ClinicalTrials.gov is both a recruitment channel and a regulatory requirement for certain trials, since patients and referring clinicians search it directly. Condition registries add a targeted pool of pre-identified candidates.
The organizations above reach engaged patient communities faster than cold outreach. Trial matching services, newsletters, and referral pathways run through groups that already hold community trust, which lifts both enrollment and retention.
Academic medical centers and specialized clinical sites bring an existing patient base and referring-physician relationships. Site selection is a recruitment decision as much as a scientific one, since site catchment shapes who can enroll.
Neurologists, neurosurgeons, psychiatrists, and audiologists refer candidates who may fit the eligibility criteria. Clear, accurate information for referrers reduces screen failures and protects the timeline.
Targeted digital campaigns and moderated patient communities extend reach beyond a single site's geography, valuable for rare neurological populations where eligible candidates are widely dispersed.
Many neurotechnology companies maintain interest lists and early-access programs that warm a candidate pool before formal enrollment opens, shortening the ramp once a study is active.